Tesi, Debiopharm lead €4.4m series-A for Kaiku Health

Finland-based growth investor Prodeko Ventures also participated in the round, alongside existing seed and early-stage investors Reaktor Ventures, Metsola Ventures and Athensmed.

Kaiku will use the funding to expand internationally and further develop its digital therapeutics pipeline. It intends to provide its platform to a growing number of healthcare providers and patients internationally.

Together with its partners, Kaiku also plans on conducting several clinical trials validating its digital therapeutics offering.

Company
Founded in 2012 and headquartered in Helsinki, Kaiku is a digital health company offering patient-monitoring software for healthcare providers across Europe.

The Kaiku platform is used in routine care by 30 clinics in Switzerland, Germany, Italy, Sweden and Finland, and has been used by 64,000 patients, according to the company.

People
Tesi – Joni Karsikas (investment manager).
Kaiku Health – Lauri Sippola (CEO, co-founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Nordics
• Healthcare
• Technology
• Finland
• Switzerland
• Venture